 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | 41% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H19N3O2 |
| Molar mass | 309.369 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
CGS-20625 is ananxiolytic drug used in scientific research. It has similar effects tobenzodiazepine drugs,[1] but is structurally distinct and so is classed as anonbenzodiazepine anxiolytic.[2][3] It produces anxiolytic andanticonvulsant effects, but with nosedative effects even at high doses, and no significant muscle relaxant effects.[4] It is orally active in humans, but with relatively low bioavailability.[5]
CGS-20625 is apositive allosteric modulator at severalGABAA receptors types. Due to itsalicyclic moiety potency atγ1subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines.[1] γ1 subunits are expressed at higher levels in thecentral amygdala.[6]
 | This article about ananxiolytic is astub. You can help Wikipedia byexpanding it. |
